Liquid Biopsies Congress

When

2019年10月10-11日
Registration from 8am

Where

英國,倫敦
London Heathrow Marriott Hotel

Liquid Biopsies Congress
-液體活檢學會-
日期:2019年10月10-11日
地點:英國,倫敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

Liquid Biopsies Congress

探索液體活檢在診斷,預測和治療上的應用

了解專家如何利用qPCR,數位PCR和次世代定序 (NGS)等技術加速液體活檢──這個癌症非侵入性診斷的發展。這次學會將以循環生物標誌物,如無細胞DNA、(cfDNA)、循環腫瘤細胞(CTC)和細胞外囊泡(EV)為焦點。

“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.

“Interesting mixture of topics; possibility to discuss with the attendees”

“Learned a lot from some of the talks”

2019年10月10日(四) – LIQUID BIOPSIES; TECHNIQUES AND TECHNOLOGIES


Keynote Address: A universal biomarker for cancer: Are we there yet?
MATT TRAU, Professor of Chemistry, Deputy Director and Co-Founder of AIBN, University of Queensland, Australia
Epigenetic reprogramming in cancer genomes creates a distinct methylation landscape encompassing clustered methylation at regulatory regions separated by large intergenic tracks of hypomethylated regions. This methylation landscape that we referred to as Methylscape is displayed by most cancer types, thus may serve as a universal cancer biomarker. We examine the effect of levels and genomic distribution of methylcytosines on the physicochemical properties of DNA to detect the Methylscape biomarker. We find that DNA polymeric behaviour is strongly affected by differential patterning of methylcytosine, leading to fundamental differences in DNA solvation and DNA-gold affinity between cancerous and normal genomes. We exploit these Methylscape differences to develop simple, highly sensitive and selective electrochemical or colorimetric one-step assays for the detection of cancer. These assays are quick, i.e., analysis time≤10minutes, and require minimal sample preparation and small DNA input from either solid or liquid biopsies.

Keynote Address: Enabling Liquid Biopsy in Cancer and Beyond
SIMON LUCAS, Innovation Field Explorer, Merck KGaA
The early detection of life-threatening conditions as well as the selection of individualized treatment options for affected patients will have significant potential to disrupt our current public health sectors. Recently, alternatives to traditional tissue biopsy, such as liquid or breath biopsy, have emerged as attractive tools for the detection and management of various diseases and especially in the therapeutic area of oncology. While cancer detection with liquid biopsy is gaining acceptance, other indications often still lack a non-invasive diagnostic test, even though precision medicine is viewed as an important concept in indications outside oncology. This talk highlights the opportunities of liquid biopsy in cancer and beyond as well as our efforts at Merck to address challenges in the field with new enabling technologies.

PRESENTATION


Morning Refreshments / Poster Presentations / One-to-One Meetings


Considerations when analyzing cell-free tumor DNA
ANDERS STAHLBERG, Associate Professor, University of Gothenburg, Sweden
• Analysis of circulating cell-free tumor DNA (ctDNA) in liquid biopsies offers new means for early cancer diagnostics, real-time monitoring of treatment efficiency and detection of relapse. Despite its potential use ctDNA remains challenging to detect and to quantify as it represents only a small fraction of all cell-free DNA.
• We have developed SiMSen-Seq, that allows allele frequencies < 0.1% to be detected. SiMSen-Seq is simple to perform, flexible in multiplexing and requires minimal DNA input.
• Here, we discuss important considerations for ctDNA analysis in plasma, including all experimental steps from sampling to data interpretation. Furthermore, the use of quality control assays enables the development of robust and standardized workflows that facilitate the implementation of ctDNA analysis into clinical routine.

Standardized analysis of extracellcular vesicles in liquid biopsies
AN HENDRIX, Assistant Professor, University of Ghent, Belgium
The identification of extracellular vesicle (EV)-associated biomarkers is challenging owing to the complexity of liquid biopsies. We 1) performed quality control studies to identify the impact of (pre-) analytical variables on biomarker identification, 2) developed reference materials to ensure standardized EV measurements, and 3) created EV-TRACK to stimulate researchers to put experimental guidelines into practice. This combined expertise boosted the identification of bacterial EV in the systemic circulation of patients with intestinal barrier dysfunction.

PRESENTATION


Lunch


Innovation in Research: From Protein Array to Companion Diagnostics to Profiling of Adverse Events
DOLORES CAHILL, Professor of Translational Science, University College Dublin, Ireland
Overview of profiling the autoantibody repertoire on high content protein arrays and using this approach to identify biomarkers, and develop diagnostics and companion diagnostics.

Clinical utility of CTC and ctDNA in metastatic and neo/adjuvant setting of breast cancer
JEAN-YVES PIERGA, Institut Curie, Department of Medical Oncology and Circulating Tumor Biomarkers Laboratory, SiRIC, Universite Paris Descartes, France
Circulating tumor cells (CTCs) have been identified as potential blood-based biomarker capable of providing prognostic and predictive information in breast cancer. Their applications include early diagnosis, prognostic assessment, detection of minimal residual disease, early detection of cancer relapse and management of metastatic disease. The clinical validity of the CTCbased liquid biopsy has been already assessed by numerous studies. Pooled analysis of large clinical data set in adjuvant, neoadjuvant and metastatic setting are now available. Recent results of clinical trial could support their clinical utility. The potential applications for circulating tumour DNA (ctDNA) in early and metastatic setting include prognosis assessment before treatment initiation, early assessment of treatment efficacy and help to guide personalized therapies.

PRESENTATION
ROBERT NEELY (Reserved), Associate Director, Pharmacodiagnostics, BMS


Afternoon Refreshments / Poster Presentations / One-to-One Meetings


Translating liquid biopsies into routine care
PANEL DISCUSSION – Speakers include:

KATARZYNA WITKOWSKA
Commercial Partnerships Manager, Genomics England, UK

KAREN SPINK
Innovation Lead - Precision Medicine, Innovate UK
ALEXANDRE HARLE
Assistant Professor, Molecular Biologist, Institut de Cancerologie de Lorraine, France
IWANKA KOZAREWA
Senior Scientist, AstraZeneca, UK
BERNHARD POLZER
Head Cellular and Molecular Diagnostics, Division Personalized Tumor Therapy, Fraunhofer-Institute for
Toxicology and Experimental Medicine ITEM-R, Germany
SIMON LUCAS
Innovation Field Explorer, Merck KGaA, Germany


Networking Drinks Reception


2019年10月11日(五) - CLINICAL APPLICATIONS

Keynote Address: A Liquid Biopsy Assay to detect Cancer
DIANA ANDERSON, Established Chair, Biomedical Sciences, University of Bradford, UK
There appeared to be no single test to identify cancer in general, but we have developed such an assay. In this modified patented Comet assay, we investigated peripheral lymphocytes from blood of 208 individuals, known as the Lymphocyte Genome Sensitivity (LGS) test. Ninety four individuals were controls. All cancers tested exhibited comparable responses. Analyses of Receiver Operating Characteristic (ROC) curves, of mean log Olive tail moments for cancer alone versus controls alone, the area under the curve was 0.93. By varying the threshold for test positivity, its sensitivity or specificity can approach 100% whilst maintaining acceptable
complementary measures. Since lymphocytes in blood only are examined, and the test has been repeated with over 900 individuals with equally valid responses, this is a useful Liquid Biopsy assay.

Liquid biopsies on the road to clinical utility
RALPH GRAESER, Senior Translational Medicine Expert, Boehringer Ingelheim
• Use of liquid biopsies in the clinic: diagnostic, prognostic, predictive?
• CTCs vs ctDNA: one or the other - or both?
• CANCER-id - a public-private partnership with the goal to standardize liquid biopsy protocols for clinical use


Morning Refreshments / Poster Presentations / One-to-One Meetings


Novel digital PCR and mutation enrichment technologies for the analysis of clinically relevant DNA alterations in liquid biopsies
MIKE MAKRIGIORGOS, Professor of Radiation Oncology, Dana Farber Cancer Institute and Harvard Medical School, USA
With the increasing interest in treatment assessment using liquid biopsy and circulating DNA, sensitive and multiplexed detection of tumor-derived alterations in blood are desirable. We provide novel forms of digital PCR, as well as mutation enrichment-based real time PCR methods that (a) enable several orders of magnitude improvement of detecting mutations or microsatellite instability than currently possible; (b) are highly multiplex-able; (c) reduce cost of analysis. Application in circulating DNA from clinical cancer samples will be presented.

A targeted multi-analyte liquid biopsy to identify early stage gynecologic cancers
JOHN MARTIGNETTIProfessor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, and Director, Laboratory of Translational Research, Western Connecticut Health Network, USA
Overwhelmingly the power and success of “liquid biopsy” has been focused on issues related to advanced disease in already diagnosed patients under active treatment. We demonstrate an approach and the feasibility of using a targeted liquid biopsy approach for detecting early stage gynecologic cancers by combining analysis of both DNA and proteins.


Lunch


CTC analysis: Latest advancements and clinical applications
EVI LIANIDOU, Professor of Analytical Chemistry - Clinical Chemistry, University of Athens, Greece
• Liquid biopsy provides a valuable source of biomarkers through simple and minimally invasive serial blood draws and represents a highly dynamic diagnostic, prognostic and theranostic tool for the management of cancer patients.
• Circulating tumor cells (CTCs) are major players in liquid biopsy and their molecular characterization offers
an exciting approach to monitor the efficacy of systemic therapies in real-time, unravel the biology of cancer cell dissemination, understand resistance to established therapies and identify gene targets and signalling pathways relevant to therapeutic interventions.
• Single-cell CTC analysis is a powerful tool to understand tumor heterogeneity and the mechanisms involved in cancer progression with potential implications for improving treatment strategies.
• This lecture will be focused on the latest developments in the detection and molecular characterization of CTCs, and their clinical applications in many types of cancer.

Prognostic and predictive value of circulating methylated DNA in metastatic colorectal cancer patients treated with regorafenib
LUDOVIC BARAULT, Senior Research Associate, Candiola Cancer Institute and the University of Torino, Italy
• Regorafenib is associated with improved progression free survival (PFS) in a subset of metastatic colorectal cancer
(mCRC) patients and no biomarkers of efficacy are available for this drug which is often associated with many toxicities.
• We previously found an association between circulating methylated DNA and outcome in chemotherapy treated mCRC patients and we hypothesized that such biomarker could be used to identify cases most likely to benefit from regorafenib (i.e. patients with PFS longer than 4 months).
• Assessment of pre and on treatment blood samples confirmed the prognostic value of circulating methylated DNA and suggest its use as biomarker for regorafenib since it may predict unresponsiveness to the treatment.

PRESENTATION
ANDREAS HAUSER, Staff Scientist, LMU, Germany


Chair’s Closing Remarks / Conference Close


 

* 活動內容有可能不事先告知作更動及調整。

演講者

議程

由於這個學會針對的是正在努力創造可以加快疾病檢測,早期診斷,加強疾病監測和治療反應的低侵入性活檢技術的研究人士,屆時預計將吸引350以上該領域的專家。

Download the Agenda (PDF)

贊助商

所有贊助商名單

地點

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海報發表

海報發表除了在休息時間之外,更與分組會議單元同時進行。製藥公司和研究機關的研究人員製所作的海報,會在通過學會審核之後,於會場內指定區域展示。

我們還會向所有與會者發放海報電子書,如果您願意,可以在會議結束後以PDF格式分享您的海報(可自由選擇)。

無論是尋找資金,就業機會還是只是想與志同道合,專心致力的研究團隊分享您的工作成果,會場內的海報都是讓您吸引眾人注目的寶貴機會。

參加海報發表,您需要先報名登記參加學會。海報展示空間有限,將依報名順序加以審核,懇請提早報名以免向隅。

我們向行業代表收取100英鎊的管理費,用於提供海報展示區和展板,指南等共同費用。代表學術機構而非營利組織的人則免收這筆費用。

海報發表的申請方法

請填寫專用表格 (下列鏈接可下載) ,在2019年9月20日前提交。但因空間有限,敬請早日申請以免向隅,如有任何問題請洽詢聯絡處。

學會的贊助商

募集贊助商

成為這個學會的贊助商或參展商,您可在融洽的氣氛中,一面和專家們交流彼此的意見,同時也有機會和各種組織代表進行官方或非官方會談,以建立彼此的合作關係。

此外我們更準備了各種贊助商配套方案,您可考量自身的預算及業務需求,選擇能讓您獲得最大投資收益的方案。

如果您有除此之外,成為贊助商來開展您宣傳活動的其他建議,也歡迎您隨時與我們連絡,我們將配合您的需求提供各種提案。

可事前預約的二十分鐘一對一個別會談

在主要會議議程的分組會議期間將舉行一系列事先預約的二十分鐘個別會談,選擇您想要會見的代表。在會議期間Global Engage的團隊將隨時待命,確保您的所有會議按時舉行。

主要會議前後的研討會

在主要會議前後,將舉辦為了對特定主題有興趣的與會者所辦的全天或半天研討會。Global Engage將協助您在研討會上進行宣傳活動,並確保夠多人出席。

學會開幕前的行銷和品牌宣傳

您也可利用Global Engage的資料庫來進行行銷,更可揭示海報,成為休息和午餐會、招待會、海報單元的贊助商來提升您的品牌知名度。此外我們也另外提供可在發給與會者的掛繩,和學會資料袋上印刷標誌以提升品牌知名度的選項。

參展

會期中,您可在會場內所設的專用區向所有的與會者發表您的技術及產品。展會區同時也是休息及午餐會,第一天傍晚舉行的招待會的會場。

演講

演講的形態

  • 30分鐘的演講
  • 以主持人或小組成員身分參加30分鐘專題研討會
  • 在學會的議程中召開1小時的研討會
募集贊助商

詳細內容請洽詢GII聯絡處。

包括簽證等各種海關所需文件,以及展示用品的通關手續皆由展商企業各自負責。

展示相關的安排(企業介紹、公司商標、提供與會者目錄中的展商資訊登錄、展示空間的裝潢、用品訂購、展示用品的擺設搬運、展示空間的文件申請、保險等)請直接與主辦方連繫。

旅遊相關疑問(住宿、機票)、當地翻譯人員、飛行與意外保險等問題,將有另外的專門業者分別提供服務。

Liquid Biopsies Congress的贊助商相關詳情請洽詢聯絡處。

關於與會者、配套方案、新募集情報等詳細資訊,請洽詢聯絡處。我們將竭誠為您提供關於您評估這場活動所需的所有資訊。

媒體合作夥伴

  • 247 Updates
  • Biocompare
  • Bentham Science
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免費電子郵件通知服務